Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


VC Term Sheets: Why We're so Pro on Anti-Dilution.

This article was originally published in Start Up

Executive Summary

A VC's perspective on anti-dilution, an often convenient, and sometimes investment saving deal provision.

You may also be interested in...

Why Entrepreneurs Should Care about Provisions that Only Directly Impact the Investors

Financing provisions that appear to only directly affect the various series of preferred stock can in fact impact the company's operations somewhere down the line. Such is the case with pay-to-play, voting rights, and a right of first refusal among investors.

VC Term Sheets: Liquidation Preference and Participating Preferred

Arthur Klausner discusses liquidation and participating preferred stock in the third part of his series on VC term sheets.

Inside the Term-Sheet Mindset of a Life Sciences VC

When deal discussions get tough and there seems to be no way to cross the chasm between the entrepreneur's valuation expectations and the VC's choking point, the savvy professional investor will likely find a way to slant the secondary terms in order to achieve a deal that works.





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts